Drug intelligence / Profile preview

erlotinib + vinflunine

Development stage: Discontinued
Lead developer: Pierre Fabre
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of erlotinib, an EGFR tyrosine kinase inhibitor, and vinflunine, a vinca alkaloid microtubule inhibitor. This combination was studied in phase I clinical trials for patients with refractory solid tumors, but showed marked toxicity that prevented further development with the tested dosing schemas.

Targets

TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on erlotinib + vinflunine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + vinflunine.

Explore the full profile